Raised levels of IFN-gamma and IL-13 are associated with pre-diabetes amongst newly diagnosed patients with tuberculosis by Hasan, Zahra et al.
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
April 2019
Raised levels of IFN-gamma and IL-13 are
associated with pre-diabetes amongst newly
diagnosed patients with tuberculosis
Zahra Hasan
Aga Khan University, zahra.hasan@aku.edu
Muhammad Irfan
Aga Khan University, muhammad.irfan@aku.edu
Qamar Masood
Aga Khan University, qamar.masood@aku.edu
Owais Ahmed
Aga Khan University, owais.ahmed@aku.edu
Shoaib Rao
Aga Khan University, shoaib.rao@aku.edu
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Pathology Commons
Recommended Citation
Hasan, Z., Irfan, M., Masood, Q., Ahmed, O., Rao, S., Moosajee, U. S., Salahuddin, N. (2019). Raised levels of IFN-gamma and IL-13
are associated with pre-diabetes amongst newly diagnosed patients with tuberculosis. Journal of the Pakistan Medical Association, 69(4),
468-473.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1174
Authors
Zahra Hasan, Muhammad Irfan, Qamar Masood, Owais Ahmed, Shoaib Rao, Umme Salama Moosajee, and
Naseem Salahuddin
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1174
Introduction
Tuberculosis (TB) results in approximately 1.7 million
deaths each year.1 Pakistan ranks 5th amongst high TB-
burden countries worldwide, with an incidence of
268/100,000 annually.1 Pakistan has a diabetes prevalence
of 6.9%, ranks 7th amongst high diabetes-burden countries
and there are estimated to be 3.5 million undiagnosed
diabetics in the country.2  In TB with diabetes, there is an
increased risk of death due to TB treatment and of TB
relapse after treatment.3 The World Health Organisation
(WHO) recommends bidirectional screening of TB in
patients with diabetes, and for diabetes in TB patients.4
Unfortunately, both TB and diabetes are often not detected
early and their public health burden is high.
Mycobacterium tuberculosis (Mtb), the causative agent
of TB, resides within macrophages and can be restricted
by the appropriate activation of T cells and macrophages
regulated by cytokines such as interferon-gamma (IFN ),
tumour necrosis factor alpha (TNF ), interleukin (IL)-2 and
IL-10. Impaired T cell mediated immune responses have
been demonstrated in Mtb infected individuals with type
2 diabetes mellitus (T2DM).5 Bacterial loads in
macrophages from diabetic individuals with TB have been
shown to be higher than in non-diabetics.6 The mechanism
responsible for immune deficiency in diabetes that leads
to exacerbation of TB is as yet unclear.
TB remains common but many patients remain unaware
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Abstract
Objective: To investigate pre-diabetes and diabetes in newly-diagnosed tuberculosis patients and
to assess the association of serum cytokine levels with diabetes status.
Methods: The cross-sectional study was conducted at Indus Hospital and The Aga Khan University
Hospital, Karachi from May to November 2015, and included patients of either gender aged 18 years
or more with a confirmed diagnosis of tuberculosis who were either newly diagnosed or had received
up to 1 month of anti-tuberculosis therapy were included. Patients were enrolled from among those
presenting to the clinics at Indus Hospital, Karachi, and the Department of Medicine, Aga Khan
University Hospital (AKUH), Karachi. The patients were tested for glycosylated haemoglobin and
random blood glucose. Diabetes was defined as HbA1c >6.5%; pre-diabetes as HbA1c=5.7-6.4%; and
normoglycaemic as HbA1c <5.7%. Serum cytokines were investigated using the Bio-plex 27, Bio-Rad
assay. SPSS version 19.0 was used for data analysis.
Results: Of the 211 subjects, 110(52%) were females and 101(48%) were males. The overall median
age of the sample was 26 years, and 100(47.3%) subjects were underweight. Of the total, 24(11.4%)
had diabetes and 45(21.3%) had pre-diabetes. Of the diabetics, only 7(29%) knew their status prior
to screening. Interferon-gamma and interleukin-13 were significantly different among tuberculosis
patients with diabetes, pre-diabetes and normoglycaemia (p<0.05). Glycosylated haemoglobin levels
showed a significant correlation with interferon-gamma levels.
Conclusions: Raised interleukin-13 and interferon-gamma levels in newly-diagnosed tuberculosis
patients with pre-diabetes.
Keywords:  Pre-diabetes, Tuberculosis, Interleukin-13, Diabetes, Interferon-gamma.
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of having diabetes. Overall, the data regarding rates of
diabetes amongst TB patients in Pakistan ranges
11- 30%.7,8
Cytokines are shown to be immune markers for TB disease
severity and outcome.9 Raised levels of pro-inflammatory
IFN , TNF   and IL-10 have been associated with advanced
TB.10,11 In diabetes, T cell IFN  responses are found to be
defective.12 In TB patients with DM and pre-DM, it has
been shown that pro-inflammatory cytokines are raised,
indicating heightened responsiveness to stimuli.13,14
There is as yet limited understanding of the immune
mechanisms responsible for poorer immune responses
to Mtb in DM patients and also the identification of
potential biomarkers of DM and TB. The current study was
planned to screen newly-diagnosed TB patients for
random blood glucose (RBG) and glycosylated
haemoglobin (HbA1c) levels. Further, we determined
serum levels of type 1 T helper (Th1) and Th2 cytokine
levels in the patients to investigate the association
between blood glucose levels and TB.
Patients and Methods
The cross-sectional study was conducted from May to
November 2015 at Indus Hospital and The Aga Khan
University Hospital (AKUH), Karachi after approval was
obtained from the ethical review committees of Aga Khan
University Hospital (AKUH), Karachi, and Indus Hospital,
Karachi. Written informed consent was taken from each
subject.
The sample size was calculated based on the prevalence
of diabetes identified in Pakistan in 2015, 6.8%.2 In TB
patients there is a 2-3 time risk of diabetes,15 thus the
prevalence rate was estimated at 13-20%.  The estimate
of the expected proportion (p) rate was set at 13-20% by
taking average proportion i.e. 16.5% with 5% desired level
of absolute precision (d) for 95% confidence interval (CI)
with 5% level of significance.
Those included were subjects from either gender aged
18 years or more with a confirmed TB diagnosis and who
were either newly-diagnosed or had received up to 1
month of anti-tuberculous therapy (ATT). Those aged less
than 18 years, and patients who had received more than
one month of ATT were excluded.
Using consecutive sampling method, patients were
enrolled from among those presenting to the TB clinics
at the two hospitals. Diagnosis of TB was made according
to the National TB Programme guidelines16 on the basis
of characteristic clinical features; chest X-rays/ a positive
sputum smear and or / Xpert TB/RIF assay (Cepheid, USA).
Sputum, when available for testing, was sent for both acid
fast bacillus (AFB) smear microscopy and Xpert testing.
In cases where sputum was not produced, patients were
identified as pulmonary TB (PTB) cases based on strong
radiological  f indings and cl inical  correlation.
Diagnosis of extrapulmonary TB (EPTB) was made on a
positive Xpert test of site-specific specimen or
histopathology confirming granulomatous inflammation,
and co-incident with clinical history. Patients with EPTB
had either pleural TB, tuberculous lymphadenopathy
(LNTB), abdominal TB or other extrapulmonary site
involvement. Detailed demographic information and
information regarding clinical algorithm was logged by
an attending medical officer on a pre-designed proforma.
Blood samples from each subject were screened for
diabetes by testing for RBG and HbA1c.
Body mass index (BMI) was calculated for each patient
based on their weight and height measurements at
baseline. The categories were set at less than 18·5 kg/m2
underweight; 18·5-22.9 kg/m2 normal weight; 23-27·4
kg/m 2  overweight;  and 27·5  kg/m 2  obese.1 7
Normal levels of HbA1c were less than 39 mmol/mol
(5.7%). Diabetes was defined by HbA1c  48 mmol/mol
(6.5%), and pre-diabetes at HbA1c 39-44 mmol/mol (5.7-
6.4 %).18
Serum samples from study subjects were tested using the
Bio-Plex Pro Human Cytokine (27-Plex Panel, Bio-Rad,
USA) as per the manufacturer's instructions.  The cytokines
detected were IFN, IL-10, IL-12p70, IL-13, IL-2, IL-5, IP-10,
MiP-1, MiP-1, IL-6, IL1-RA, GM-CSF, RANTES, IL-1,
Eotaxin, Basic FGF, VEGF, PDGF-, MCP-1, IL-8, IL15, IL-17,
G-CSF, IL-12p70, IL17A, IL-9 and TNF-. Tests were
performed on the Luminex 200 system (MERCK
laboratories, USA).
Data analysis was done using SPSS version 19.0. Mann-
Whitney U test was used to compare non-parametric
variables. Significance of 95% CI was used to determine
significant difference between variables which was set at
p0.05.
Results
Of the 216 patients initially approached, 4(1.8%) refused
to give a blood sample while 1(0.45%) was lost due to
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haemolysis. After data collection 1(0.45%) patient had to
be excluded due to old age which was identified later.
The final sample, as such, stood at 211(97%). Of them,
110(52%) were females and 101(48%) were males. The
overall median age of the sample was 26 years, and
100(47.3%) subjects were underweight (Table 1).
The BMI values were available for 167(79%) subjects and,
among them, median BMI was 17.78 kg/m2.  The median
number of members in each household was 7, and
76(36%) cases had a family history / household contact
with TB patients.
Overall, 165(78.2%) cases were new and 46 (21.8%) were
re-treatment cases. At the time of recruitment, 135(63.5%)
were newly-diagnosed and had not received ATT while
76 (36.5%) cases had received one month of ATT.
In terms of co-morbid conditions, 2(0.9%) patients had
human immunodeficiency virus (HIV) infection, 3(1.3%)
subjects had viral hepatitis B or C, 3(1.3%) were intravenous
drug users (IDUs) and 1(0.45%) had an autoimmune
disease. Besides, 7(3.3%) subjects were known diabetics
and were on treatment  for  hyperglycaemia.
Further, there were 172(81%) cases of PTB and 39(19%)
of EPTB (Table 2). Sputum was available for testing in 150
(87%) cases. Where sputum was not produced, patients
were identified as PTB cases based on strong radiological
findings and clinical correlation. On sputum testing,
70(46.7%) had a positive AFB smear. Of the 144(68%) cases
in which sputum Xpert test was peformed, 121(84%) had
a positive result; 118 (97.5%) had rifampicin-susceptible
Mtb, 1 (0.8%) had rifampicin-resistant Mtb, and 2(1.6%)
had indeterminate results.
Overall, 70 (41%) of 172 PTB patients were diagnosed on
the basis of AFB smear being positive, and 121 (70%) were
diagnosed via positive Xpert TB result.
Of the PTB cases, 85(54.1%) had moderate disease on
chest radiograph followed by advanced disease 54(34.4%)
and minimal disease in 18 (11.5%).
Total  n (%)
Age (years) (n=211)  25 100 (47.4)
26-50 76 (36.0)
>50 35 (16.6)
Gender (n=211) Male 101 (47.9)
Female 110 (52.1)
BMI kg/m2 with Categories (n=167) Underweight (<18.5) 100 (47.3)
Normal (18.5-22.9) 44 (20.9)
Overweight (23-27.4) 11 (5.7)
Obese (27.5) 12 (5.7)
Site of TB Pulmonary TB 172(81.5)
Extra Pulmonary TB 39(18.5)
Category of Treatment (n=211) New treatment 165 (78.2)
Retreatment 46 (21.8)
Family History of TB (n=211) Positive Family History 76 (36.0)
No Family History 135 (64.0)
BMI=body mass index; TB=tuberculosis
Table-1: Description of study sample .
n (% of total) Result n (%)
PTB cases 172 (81.5%)
Sputum  AFB Smear 150 (87%) Positive 70 (46.7)
Negative 80 (53.3)
Sputum Xpert MTB/RIF 144 (84%) Positive 121 (84)
Negative         23 (16)
Xpert MTB/RIF Result 121 (57.3%) Not Detected 118 (97.5)
Indeterminate 2 (1.7)
Detected 1 (0.8)
Chest X-Ray 157 (74.4%) Minimal 18(11.5)
Moderate 85(54.1)
Advanced 54(34.4)
EPTB cases 39 (18.5%)
Category of TB Pleural 16 (41)
Abdominal 9 (23)
Lymph node 7 (17.9)
Bone and joint 2 (5.1)
Others 5 (12.8)
PTB=pulmonary tuberculosis; EPTB=extrapulmonary tuberculosis;
AFB=acid-fast bacillus; Xpert TB, Xpert MTB/RIF assay, Cepheid, USA.
Table-2: Microbiological and Radiological description of TB cases (n=211).
Total Median HbA1c IQR=Median (Q3 -Q1) RBG
n (%) Age (Years) IFCC (mmol/mol) NGSP HbA1c  % IQR=Median (Q3 -Q1)
Non-Diabetics 142 (67.30%) 23 34 mmol/mol (37-31) 5.30%(5.50-5.00) 95 (108-89)
Pre-Diabetics 45 (21.30%) 40 40 mmol/mol  (42-39) 5.80%(6.00-5.70) 100 (122-93)
Diabetics 24 (11.40%) 50 92 mmol/mol (108-81) 10.6%(12.00-9.55) 281 (390-191)
Total 211 (100%) 26 37 mmol/mol (40-32) 5.50%(5.80-5.10) 98 (118-90)
p-value ---- p<0.0001* p<0.0001* p<0.0001*
RBG=random blood glucose, IQR=inter-quartile range, HbA1c=Glycosylated haemoglobin
Table-3: Characteristics of study subjects as per diabetes status (n=211).
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Of the 39 EPTB cases, 32(82%) had a normal chest X-ray.
The EPTB cases comprised pleural 16(41%), abdominal
9(23%), lymph-node TB 7(18%), bone and joint 2 (5%),
and the remaining 5(13%) cases had additional sites
involved.
Based on HbA1c and RBG test results, 142 (67.3%) patients
had normal glycaemic levels, 45(21.3%) were pre-diabetics
and 24(11.4%) were diabetics (Table 3).  The median HbA1c
levels of normoglycaemics was 5.3%, pre-diabetics 5.8%
and diabetics 10.6%. Median RBG levels were 95 g/dl for
normal, 100 g/dl for pre-diabetics and 281 g/dl for
diabetics.
TB patients with diabetes were comparatively older than
the rest (p<0.001). Of the diabetic patients, 17(71%) were
newly-diagnosed while 7(29%) already knew they had
diabetes.
Among the diabetics, 14(58%) were males and 10(42%)
were females (Table 4). Among the pre-diabetics,
29(28.7%) were males compared to 16(15.5%) women
((p=0.026).
Among the 100(47.3%) underweight individuals, 77(77%)
were non-diabetics, 18(18%) pre-diabetics and 5(5%) were
diabetics. Amongst TB patients with normal weight, the
corresponding values were 30(68%), 7(16%) and 7(16%).
Among the overweight TB patients, the values were
4(36.4%) non-diabetics, 4(36.4%) pre-diabetics and 3(27%)
diabetics. In the obese TB cases, there were 4(33.3%) non-
diabetics, 6(50%) pre-diabetics and 2(16.7%) diabetics.
Circulating serum levels of cytokines were measured in
75 (35.5%). Of them, 13 (17.3%) had diabetes, 24 (32%)
had pre-diabetes, and 38(51%) were non-diabetics.
Significantly different levels of IFN (p=0.028) and IL-13
(p=0.003) were observed among normoglycaemic,
diabetic and pre-diabetic cases. IFN levels in individuals
with pre-DM were greater than those with DM (p=0.028)
and normoglycaemic (p=0.007) TB patients. Also, IL-13
was raised in pre-DM compared to DM (p=0.003) and
normoglycaemics (p=0.001).
Levels of IL-10, IL-12p70, IL-2 and IL-5 were comparable
between normoglycaemic, diabetic and non-diabetic TB
patients (Table 5).
HbA1c levels showed a weak but significant correlation
with IFN (p=0.23, rho=0.262).
Discussion
This, to our knowledge, is the first study to identify rates
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Total  n (%) Non-Diabetics  n (%) Pre-Diabetics  n (%) Diabetics  n (%)
Gender Male 101 (47.9) 58 (57.4) 29 (28.7) 14 (13.9)
Female 110 (52.1) 84 (76.4) 16 (15.5) 10 (9.1)
BMI (kg/m2) with Categories (n=167) Underweight (<18.5 (kg/m2)) 100 (60) 77 (77) 18 (18) 5 (5)
Normal (18.5-22.9) 44 (26.3) 30 (68.2) 7 (16.2) 7 (16.2)
Overweight (23-27.4) 11 (6.6) 4 (36.4) 4 (36.4) 3 (27.3)
Obese (27.5) 12 (7.2) 4 (33.3) 6 (50) 2 (16.7)
Site of TB Pulmonary TB 172 (81.5) 109 (63.4) 39 (22.7) 24 (14)
Extra Pulmonary TB 39 (28.5) 33 (84.6) 6 (15.4) 0
Category of Treatment New treatment 165 (78.2) 108 (65.5) 36 (21.8) 21 (12.7)
Retreatment 46 (21.8) 34 (73.9) 9 (19.6) 3 (6.5)
BMI=body mass index are given in kg/m2. All values represent the absolute number followed by the percentage in parentheses.
Non-diabetics or normoglycaemics with HbA1c <5.7%; Pre-diabetics with HbA1c 5.7-6.4% and Diabetics with HbA1c >6.4%
Table-4: Comparison of TB patients as per glycaemic levels.
n IFN  IL-10 IL-12p70 IL-13 IL-2 IL-5 TNF-
Mean±SD (pg/ml) Mean±SD (pg/ml) Mean±SD (pg/ml) Mean±SD (pg/ml) Mean±SD (pg/ml) Mean±SD (pg/ml) Mean±SD (pg/ml)
Normal 38 27.58 ±89.65 155.56 ± 490.18 117.66 ± 437.49 2.90±17.85 0.00 25.24 ±155.60 112.07±416.08
Pre-diabetic 24 444.11 ±1298.58 261.47 ± 747.79 362.00 ± 835.35 72.23 ±210.24 63.20 ± 220.39 102.63 ±263.72 730.74±2448.77
Diabetic 13 257.30 ±746.37 0.00 128.16 ± 462.07 68.00 ±245.19 64.34 ±231.98 76.84 ± 277.05 1700.78±5881.97
p-value 0.028* NS NS 0.003* NS NS NS
IFN = interferon-gamma; IL, interleukin; TNF=tumor necrosis factor-alpha.
Table-5: Circulating cytokine values.
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of pre-DM in a cohort of newly-diagnosed TB patients in
Pakistan. Also, it identified IFN and IL-13 as biomarkers
of individuals with TB and pre-DM. Pre-diabetes is a state
which can often be managed with exercise and healthy
eating. Identification of diabetes or pre-diabetes, defined
also as intermediate diabetes, is important as uncontrolled
blood glucose levels result in unfavourable outcomes in
TB patients.19
A study in Karachi recently showed that diabetics were
10 times more likely to have TB than non-diabetics.20
Previous studies have reported rates of diabetes amongst
TB patients as 11-30% (7, 8). This has further varied to 6%
of newly-diagnosed diabetics amongst TB patients21 while
another revealed that there were 39%8 diabetics amongst
TB patients.
The current study identified 11.4% cases of diabetes and
21.3% cases of pre-diabetes. The percentage of diabetics
found here and in previous studies is higher than the
prevalence of 6.9% shown nationwide.2 These variations
could be due to the cohort tested and also due to
differences in methods used to assess diabetes, as there
may be differences due to cut-offs by fasting blood glucose
(FBG), HbA1c and oral glucose tolerance test (OGTT)
methods.
The higher proportion of TB patients with pulmonary
compared with EPTB matches the trends reported globally.
Most patients were under the age of 25 years, meaning
TB occurs predominantly in young adults.1 The trend of
high household contacts for each individual was similar
to those reported previously.22 The rate of 36% amongst
those with prior family history of TB suggests that the
majority of TB cases were a result of new contact with TB
patients.  The age group of diabetics showed an older age
distribution than those who didn't have diabetes, as shown
previously.8 The reduced BMI in TB patients with the
majority of cases being underweight fits previous reports.8
When patients were further differentiated as per BMI
categories17 and were correlated with their glycaemic
status, it was apparent that amongst the overweight and
obese TB patients there was a larger proportion of cases
who were pre-diabetic and diabetic compared to the
proportion of pre-diabetic and diabetic cases found in
the underweight and normal weight groups. This
correlates with previous reports that showed an increased
association of diabetes with raised BMI in TB patients.7
An impaired T cell mediated immune response has been
demonstrated.5 Bacterial loads in macrophages from
diabetic individuals with TB are higher than in non-
diabetics.6 This leads to less favourable outcomes in TB
patients who have diabetes.
Pre-diabetes is a state which can often be managed with
exercise and healthy eating. We found that 21% of newly-
diagnosed TB patients were pre-diabetic. Further, it was
apparent that IFN and IL-13 levels were significantly
higher in those with pre-DM compared with DM and
normoglycaemic TB patients.
A recent study showed there was a diminished
inflammatory response to Mtb in individuals who had
latent TB coincident with pre-diabetes.23 Separately, certain
inflammatory markers such as immunoglobulin E (IgE),
IL-4, IL-10, and tryptase have been positively associated
with pre-diabetes or T2DM.24 Our data indicating an
increase in IFN levels in pre-DM TB patients confers with
previous reports.13 However, a study observed an increase
in additional cytokines Type 1 and Type 2.13 Another
difference from this study was that we observed a weak
but significant correlation between IFN levels and HbA1c
levels in TB patients, which was in contrast to that observed
by a previous study.13
It is of note that IL-13 was found to be raised in TB patients
with pre-DM. Our observation that IL-13 levels are reduced
in DM is in line with reduced glycaemic control.  IL-13 is
a Th2 cytokine known to mediate macrophage alternate
activation. IL-13 knockout mice have been shown to
display hyperglycaemia resulting in hepatic insulin
resistance and systemic metabolic dysfunction.25
Therefore, IL-13 is important for the regulation of glucose
metabolism. During TB treatment there is a transient state
of hyperglycaemia.26 This is likely to be further raised in
those with previously raised blood glucose levels.
Uncontrolled hyperglycaemia leads to chronic
inflammation. Therefore, in the absence of a homeostatic
balance of cytokines immune responses to Mtb infection
will be defective.
Conclusions
IL-13 and IFN were identified as biomarkers of pre-
diabetes in TB patients. There is a need for early
identification and management of diabetes and pre-
diabetes in TB.
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